Toagosei Company, Ltd.

Seiko Epson Corporation

Nagoya University

Keio University

Kurume University

Japan Tissue Engineering Co., Ltd.

Mikio Niwa

Tetsuhiko Yoshida

Nahoko Kobayashi

Masaji Okamoto

Ken-ichiro Hata

Masatoki Watanabe

Tomoe Matsumoto

Chikara Shinohara

Kenichi Tanaka

Hitoshi Fukushima

Makoto Sawada

Nahoko Baileykobayashi

Jun Kudo

Masato Hanamura

Makoto Asano

Toshiaki Segawa

Michio Sata

Keiichi Mitsuyama

Katsuhiko Matsuo

Tomoko Naoe

Masabumi Shibuya

Tosiaki Segawa

Tomohiro Izumiyama

Ken-Ichiro Hata

Sawada Makoto

Izumiyama Tomohiro

Provided are a synthetic peptide that induces the reprogramming of a differentiated cell, a reprogramming-inducing pharmaceutical composition that contains this synthetic peptide, and a method for producing an undifferentiated cell from a differentiated cell using this synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a reprogramming-inducing peptide sequence formed of the amino acid sequence given by SEQ ID NO: 1 or a modified amino acid sequence thereof. The method for producing an undifferentiated cell provided by the present invention includes inducing the reprogramming of a target cell by culturing a cell culture which contains the target cell and to which the synthetic peptide has been supplied.

Synthetic peptide and use thereof

This invention provides a TNFR2 expression-inducing composition including as an active ingredient a peptide having TNFR2 expression-inducing activity, and a method for producing cells that express TNFR2 selectively by use of the composition. The cell production method provided by this invention includes: culturing at least one species of cells capable of expressing TNF receptor 2, and supplying the cells with a synthetic peptide consisting of a nuclear localization signal sequence (NLS) or a nucleolar localization signal sequence (NoLS) to enhance TNFR2 expression in the cells.

Synthetic peptide that induces expression of TNF receptor 2 and use thereof

An advantage of some aspects of the invention is to provide an antibody against an amyloid precursor protein signal peptide. The invention provides an amyloid precursor protein signal peptide.

Antibody against amyloid precursor protein signal peptide

A method for manufacturing at least one kind of eukaryotic cells or a biosynthetic substance derived from the eukaryotic cells by proliferating the cells, which includes preparing an artificially synthesized peptide for promoting proliferation of the at least one kind of eukaryotic cells, incubating the eukaryotic cells in a culture medium, and adding the synthesized peptide at least once to the culture medium during the incubation process. The synthesized peptide includes an amino acid sequence selected from SEQ ID NOS: 1 to 18, and an amino acid sequence selected from SEQ ID NOS: 19 to 97.

Cell proliferation-promoting peptide and use thereof

The method for transferring a foreign substance provided by the present invention includes the steps of: preparing a construct for transferring a foreign substance that contains a carrier peptide fragment including either the amino acid sequence WRRQARFK (SEQ ID NO. 1) or any amino acid sequence formed by the substitution, deletion, and/or addition (insertion) of 1, 2, or 3 amino acid residues in the amino acid sequence, and a foreign substance of interest that is bonded to the N-terminus and/or C-terminus of the carrier peptide fragment; supplying the construct for transferring a foreign substance to a test sample that contains a target eukaryotic cell; and incubating the test sample that has been supplied with the construct for transferring a foreign substance to thereby transfer the construct into the eukaryotic cell in the test sample.

Carrier peptide fragment and use thereof

A cell proliferation promoter includes, as an active ingredient, an artificially synthesized peptide that includes (A) an amino acid sequence constituting a membrane-permeable peptide and (B) an amino acid sequence selected from SEQ ID NOs: 19 to 103 or an amino acid sequence formed by substituting, deleting and/or adding one or several amino acid residues in the selected amino acid sequence.

A method for transferring a foreign substance includes the steps of: preparing a construct for transferring a foreign substance that contains a carrier peptide fragment including either the amino acid sequence KKRTLRKNDRKKR (SEQ ID NO. 1) or an amino acid sequence formed by the substitution, deletion, and/or addition (insertion) of 1, 2, or 3 amino acid residues in the amino acid sequence, and a foreign substance of interest that is bonded to the N-terminus and/or C-terminus of the carrier peptide fragment; supplying the construct for transferring a foreign substance to a test sample that contains a target eukaryotic cell; and incubating the test sample that has been supplied with the construct for transferring a foreign substance to thereby transfer the construct into the eukaryotic cell in the test sample.

An epitope peptide is provided, which is capable of binding specifically to an antibody characteristic of Crohn's disease that is specifically observed in patients with Crohn's disease, together with a test method for conveniently and rapidly determining whether a subject is affected by Crohn's disease by use of the above peptide. The epitope peptide to the Crohn's disease antibody comprises a peptide having an amino acid sequences represented by any one of SEQ ID NOS: 1 to 3 or a salt thereof. A test reagent and a test method for Crohn's disease are provided, which comprise the peptide as an active ingredient.

Crohn's disease antibody epitope peptide and reagent for testing Crohn's disease

A novel polypeptide is provided, which can be utilized to treat diseases accompanying neovascularization, such as solid tumors, and is useful as a low molecular weight VEGF inhibitor. The polypeptide contains immunoglobulin-like domain 1 and immunoglobulin-like domain 2 of the extracellular domain of the VEGF receptor KDR. Since it has smaller molecular weight than the conventional polypeptides with retaining VEGF inhibitory activity, it is expected that it can be readily expressed using recombinant DNA techniques and infiltrates into diseased sites more quickly.

VEGF-binding KDR polypeptide

An object of the present invention is to provide a low molecular weight VEGF inhibitor that can be utilized to treat diseases accompanying neovascularization, such as solid tumors. It was found that a polypeptide containing immunoglobulin-like domain 1 and immunoglobulin-like domain 2 but neither immunoglobulin-like main 6 nor immunoglobulin-like domain 7 of the extracellular domain of the VEGF receptor FLT possess VEGF inhibitory activity.

VEGF-binding polypeptide

Growing community of inventors

Tsukuba, Japan

Mikio Niwa